Back to top

Gilead Sciences, Inc. (GILD)

(Real Time Quote from BATS)

$70.02 USD


-0.53 (-0.75%)

Updated Nov 15, 2018 02:42 PM ET

Add to portfolio

1-Strong Buy 1        

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
Strong Buy
Strong Sell

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

B Value | F Growth | F Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Company Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.

General Information

Gilead Sciences, Inc.



Phone: 650-574-3000

Fax: 650-578-9264



Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 9/30/2018
Next EPS Date 2/5/2019

EPS Information

Current Quarter EPS Consensus Estimate 1.74
Current Year EPS Consensus Estimate 6.87
Estimated Long-Term EPS Growth Rate -4.00
Next EPS Report Date 2/5/2019

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 70.55
52 Week High 89.54
52 Week Low 64.27
Beta 1.01
20 Day Moving Average 7,205,037.50
Target Price Consensus 88.88


% Price Change
4 Week -6.70
12 Week -4.43
YTD -1.52
% Price Change Relative to S&P 500
4 Week -2.99
12 Week 1.24
YTD -2.77
Share Information
Shares Outstanding (millions) 1,293.62
Market Capitalization (millions) 91,264.87
Short Ratio NA
Last Split Date 1/28/2013
Dividend Information
Dividend Yield 3.23%
Annual Dividend $2.28
Payout Ratio 0.36
Change in Payout Ratio 0.22
Last Dividend Payout / Amount 9/13/2018 / $0.57

Fundamental Ratios

P/E (F1) 10.26
Trailing 12 Months 10.06
PEG Ratio -2.57
EPS Growth
vs. Previous Year -23.77%
vs. Previous Quarter -2.86%
Sales Growth
vs. Previous Year -14.07%
vs. Previous Quarter -0.92%
Price Ratios
Price/Book 3.97
Price/Cash Flow 7.33
Price / Sales 4.10
9/30/18 39.32
6/30/18 41.57
3/31/18 45.49
9/30/18 12.73
6/30/18 13.79
3/31/18 15.63
Current Ratio
9/30/18 3.45
6/30/18 3.00
3/31/18 2.84
Quick Ratio
9/30/18 3.37
6/30/18 2.92
3/31/18 2.75
Operating Margin
9/30/18 37.90
6/30/18 39.49
3/31/18 41.23
Net Margin
9/30/18 7.12
6/30/18 9.52
3/31/18 14.03
Pre-Tax Margin
9/30/18 39.99
6/30/18 42.75
3/31/18 48.38
Book Value
9/30/18 17.78
6/30/18 16.77
3/31/18 15.84
Inventory Turnover
9/30/18 5.40
6/30/18 4.86
3/31/18 4.17
9/30/18 1.09
6/30/18 1.23
3/31/18 1.32
Debt to Capital
9/30/18 52.24
6/30/18 55.13
3/31/18 56.87